FMRP regulates an ethanol-dependent shift in GABA B R function and expression with rapid antidepressant properties

Nature Communications

Volumn 7, Issue , 2016, Pages

  Wolfe, Sarah A ^a   Workman, Emily R ^a   Heaney, Chelcie F ^a   Niere, Farr ^a   Namjoshi, Sanjeev ^a   Cacheaux, Luisa P ^a   Farris, Sean P ^a   Drew, Michael R ^a   Zemelman, Boris V ^a   Harris, R Adron ^a   Raab Graham, Kimberly F ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALCOHOL; CALCIUM; FRAGILE X MENTAL RETARDATION PROTEIN;

CALCIUM; ETHANOL; GENE; GENE EXPRESSION; MENTAL HEALTH; MOLECULAR ANALYSIS; NERVOUS SYSTEM DISORDER; PROTEIN; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANQUILIZING ACTIVITY;

MUS;

EID: 84989245521     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12867     Document Type: Article

References (66)

1. Boden, J. M. & Fergusson, D. M. Alcohol and depression. Addiction 106, 906-914 (2011).
2. Koob, G. F. & Le Moal, M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24, 97-129 (2001).
3. Skolnick, P., Popik, P. & Trullas, R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol. Sci. 30, 563-569 (2009).
4. Abdallah, C. G., Sanacora, G., Duman, R. S. & Krystal, J. H. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu. Rev. Med. 66, 509-523 (2015).
5. Li, N. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964 (2010).
6. Workman, E. R., Niere, F. & Raab-Graham, K. F. mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling. Neuropharmacology 73, 192-203 (2013).
7. Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945 (2004).
8. Workman, E. R. et al. Rapid antidepressants stimulate the decoupling of GABA receptors from GIRK/Kir3 channels through increased protein stability of 14-3-3eta. Mol. Psychiatry 20, 298-310 (2015).
9. Lovinger, D. M., White, G. & Weight, F. F. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 243, 1721-1724 (1989).
10. Nosyreva, E. et al. Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J. Neurosci. 33, 6990-7002 (2013).
11. Raab-Graham, K. F., Workman, E. R., Namjoshi, S. & Niere, F. Pushing the threshold: How NMDAR antagonists induce homeostasis through protein synthesis to remedy depression. Brain Res. 10.1016/j.brainres.2016.04.020 (2016).
12. Huber, K. M., Gallagher, S. M., Warren, S. T. & Bear, M. F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl Acad. Sci. USA 99, 7746-7750 (2002).
13. Vanderklish, P. W. & Edelman, G. M. Dendritic spines elongate after stimulation of group 1 metabotropic glutamate receptors in cultured hippocampal neurons. Proc. Natl Acad. Sci. USA 99, 1639-1644 (2002).
14. Hou, L. et al. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 51, 441-454 (2006).
15. Nalavadi, V. C., Muddashetty, R. S., Gross, C. & Bassell, G. J. Dephosphorylation-induced ubiquitination and degradation of FMRP in dendrites: a role in immediate early mGluR-stimulated translation. J. Neurosci. 32, 2582-2587 (2012).
16. Bassell, G. J. & Warren, S. T. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60, 201-214 (2008).
17. Hagerman, R. & Hagerman, P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol. 12, 786-798 (2013).
18. Ron, D. & Messing, R. O. Signaling pathways mediating alcohol effects. Curr. Top. Behav. Neurosci. 13, 87-126 (2013).
19. Placzek, A. N. et al. Translational control of nicotine-evoked synaptic potentiation in mice and neuronal responses in human smokers by eIF2alpha. Elife 5, doi:10.7554/eLife.12056 (2016).
20. Lovinger, D. M. & Roberto, M. Synaptic effects induced by alcohol. Curr. Top. Behav. Neurosci. 13, 31-86 (2013).
21. Luscher, C. & Malenka, R. C. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 69, 650-663 (2011).
22. Smith, L. N. et al. Fragile X mental retardation protein regulates synaptic and behavioral plasticity to repeated cocaine administration. Neuron 82, 645-658 (2014).
23. Porsolt, R. D., Bertin, A., Blavet, N., Deniel, M. & Jalfre, M. Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur. J. Pharmacol. 57, 201-210 (1979).
24. Autry, A. E. et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91-95 (2011).
25. Blednov, Y. A. et al. Linking GABA(A) receptor subunits to alcohol-induced conditioned taste aversion and recovery from acute alcohol intoxication. Neuropharmacology 67, 46-56 (2013).
26. Rhodes, J. S., Best, K., Belknap, J. K., Finn, D. A. & Crabbe, J. C. Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. Physiol. Behav. 84, 53-63 (2005).
27. David, D. J. et al. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62, 479-493 (2009).
28. Surget, A. et al. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol. Psychiatry 64, 293-301 (2008).
29. American Psychiatric Association & American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5 5th edn (American Psychiatric Association, Washington, D.C., 2013).
30. Blednov, Y. A., Stoffel, M., Chang, S. R. & Harris, R. A. Potassium channels as targets for ethanol: studies of G-protein-coupled inwardly rectifying potassium channel 2 (GIRK2) null mutant mice. J. Pharmacol. Exp. Ther. 298, 521-530 (2001).
31. Treit, D. & Fundytus, M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol. Biochem. Behav. 31, 959-962 (1988).
32. Margeta-Mitrovic, M., Jan, Y. N. & Jan, L. Y. A trafficking checkpoint controls GABAB receptor heterodimerization. Neuron 27, 97-106 (2000).
33. Ginsburg, B. C. et al. Mouse breathalyzer. Alcohol Clin. Exp. Res. 32, 1181-1185 (2008).
34. Cajigas, I. J. et al. The local transcriptome in the synaptic neuropil revealed by deep sequencing and high-resolution imaging. Neuron 74, 453-466 (2012)
35. Darnell, J. C. et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247-261 (2011).
36. Graber, T. E. et al. Reactivation of stalled polyribosomes in synaptic plasticity. Proc. Natl Acad. Sci. USA 110, 16205-16210 (2013).
37. Zhou, Z., Yuan, Q., Mash, D. C. & Goldman, D. Substance-specific and shared transcription and epigenetic changes in the human hippocampus chronically exposed to cocaine and alcohol. Proc. Natl Acad. Sci. USA 108, 6626-6631 (2011).
38. tom Dieck, S. et al. Direct visualization of newly synthesized target proteins in situ. Nat. Methods 12, 411-414 (2015).
39. Hendel, T. et al. Fluorescence changes of genetic calcium indicators and OGB-1 correlated with neural activity and calcium in vivo and in vitro. J. Neurosci. 28, 7399-7411 (2008).
40. Jaso, B. A. et al. Therapeutic modulation of glutamate receptors in major depressive disorder. Curr. Neuropharmacol. (2016).
41. Dictenberg, J. B., Swanger, S. A., Antar, L. N., Singer, R. H. & Bassell, G. J. Dev. Cell 14, 926-939 (2008).
42. Muddashetty, R. S., Kelic, S., Gross, C., Xu, M. & Bassell, G. J. J. Neurosci. 27, 5338-5348 (2007).
43. Niere, F., Wilkerson, J. R. & Huber, K. M. J. Neurosci. 32, 5924-5936 (2012).
44. Soden, M. E. & Chen, L. Fragile X protein FMRP is required for homeostatic plasticity and regulation of synaptic strength by retinoic acid. J. Neurosci. 30, 16910-16921 (2010).
45. Muddashetty, R. S. et al. Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation, and mGluR signaling. Mol. Cell 42, 673-688 (2011).
46. Antar, L. N., Li, C., Zhang, H., Carroll, R. C. & Bassell, G. J. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Mol. Cell. Neurosci. 32, 37-48 (2006).
47. Christie, S. B., Akins, M. R., Schwob, J. E. & Fallon, J. R. The FXG: a presynaptic fragile X granule expressed in a subset of developing brain circuits. J. Neurosci. 29, 1514-1524 (2009).
48. Gatto, C. L., Pereira, D. & Broadie, K. GABAergic circuit dysfunction in the Drosophila Fragile X syndrome model. Neurobiol. Dis. 65, 142-159 (2014).
49. DHulst, C. et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain. Res. 1121, 238-245 (2006).
50. Henderson, C. et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with Arbaclofen. Sci. Transl. Med. 4, 152ra128-152ra128 (2012).
51. Qin, M. et al. R-Baclofen reverses a social behavior deficit and elevated protein synthesis in a mouse model of fragile X syndrome. Int. J. Neuropsychopharmacol. 18, pyv034 (2015).
52. Gibson, J. R., Bartley, A. F., Hays, S. A. & Huber, K. M. J. Neurophysiol. 100, 2615-2626 (2008).
53. Osterweil, E. K., Kind, P. C. & Bear, M. F. Lifting the mood on treating fragile X. Biol. Psychiatry 72, 895-897 (2012).
54. Kenny, P. J. Epigenetics, microRNA, and addiction. Dialogues Clin. Neurosci. 16, 335-344 (2014).
55. Holmes, A., Spanagel, R. & Krystal, J. H. Glutamatergic targets for new alcohol medications. Psychopharmacology (Berl.) 229, 539-554 (2013).
56. Farris, S. P., Arasappan, D., Hunicke-Smith, S., Harris, R. A. & Mayfield, R. D. Transcriptome organization for chronic alcohol abuse in human brain. Mol. Psychiatry 20, 1438-1447 (2014).
57. Krishnan-Sarin, S., OMalley, S. & Krystal, J. H. Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. Alcohol Res. Health 31, 400-407 (2008).
58. Spencer, K. B., Mulholland, P. J. & Chandler, L. J. FMRP mediates chronic ethanol-induced changes in NMDA, Kv4.2, and KChIP3 expression in the hippocampus. Alcohol Clin. Exp. Res. 40, 1251-1261 (2016).
59. Chandler, L. J., Sumners, C. & Crews, F. T. Ethanol inhibits NMDA receptor-mediated excitotoxicity in rat primary neuronal cultures. Alcohol Clin. Exp. Res. 17, 54-60 (1993).
60. Sosanya, N. M. et al. Degradation of high affinity HuD targets releases Kv1.1 mRNA from miR-129 repression by mTORC1. J. Cell Biol. 202, 53-69 (2013).
61. Varga, V. et al. Fast synaptic subcortical control of hippocampal circuits. Science 326, 449-453 (2009).
62. Quinlan, E. M., Olstein, D. H. & Bear, M. F. Bidirectional, experiencedependent regulation of N-methyl-D-aspartate receptor subunit composition in the rat visual cortex during postnatal development. Proc. Natl Acad. Sci. USA 96, 12876-12880 (1999).
63. Jain, R. et al. RIP-Chip analysis: RNA-binding protein immunoprecipitationmicroarray (Chip) profiling. Methods Mol. Biol. 703, 247-263 (2011).
64. Keene, J. D., Komisarow, J. M. & Friedersdorf, M. B. RIP-Chip: the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts. Nat. Protoc. 1, 302-307 (2006).
65. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).
66. Cohen, J. Statistical power analysis. Curr. Dir. Psychol. Sci. 1, 98-101 (1992).